ABIVAX (ABVX) AGM 2025 summary

Opening remarks and agenda

• Meeting opened with a business review, financial update, and closing remarks outlined as the main agenda items.

Financial performance review

• Operating income rose to €12.4M in 2024, a 169% increase from 2023.

• Operating expenses increased by 40% to €185.4M, mainly due to higher R&D and administrative costs.

• Net loss widened to €176.2M in 2024, up 19% from the previous year.

• Cash at year-end was €103.6M, with funding expected to last into Q4 2025.

• Share price declined 34.1% in 2024 but rebounded with a 10.2% YTD gain in 2025 amid positive trial momentum.

Board and executive committee updates

• Sylvie Grégoire appointed Board Chair in July 2024; Mark Stenhouse joined as Board Observer in November 2024; Dominik Höchli, M.D. joined the Board in April 2025.

• Leadership team brings extensive experience in drug development and commercialization.